“And then as you enter into Q, you know, FY ‘26, you pick up the Ardian piece as well and CAS keeps going.”

In context

“in CRM, think leadless, conduction system pacing, EBICD. And, again, as I mentioned, the commentary structural heart's in a great place and with strong evidence and that we'll keep building upon and product improvements that have come out and Evolut FX plus and, you know, I think just better commercial execution against the main competitor there from our team. I mentioned cardiac surgery, where we've, you know, revamped the product lineup, refreshed it over the last two years, and now it's been growing at high-single-digits. So you have all that in this base business that we don't see changing going forward, that mid-single-digit growth that we've seen over the last 10 quarters. And now you add the contributions from CAS and RTN on top of that, that you, you know, you'll accelerate in Q4. And then as you enter into Q, you know, FY ‘26, you pick up the Ardian piece as well and CAS keeps going. Travis Steed: Great. Thanks a lot for that. Geoff Martha: Hope that helps. Travis Steed: Yes, it does. Thank you. Ryan Weispfenning: Thank you, Travis. Next question, Brad. Brad Welnick: We'll take the next question from Matt Miksic at Barclays. Matt, please go ahead. Matt Miksic: Thanks so much. So I wanted to just follow-up on the other sort of soft spot in the quarter here, for full vascular. That went from like a mid-single-digit growth in previous quarters to this low-single-digit decline. And I guess similar to the questions around distributor stocking is timing for turning that around confidence that can kind of turn the corner here since that really was the only business in CV that pulled down a little bit on a pretty solid mid-single-digit growth portfolio average? Thanks. Geoff”